The U.S. Food and Drug Administration has approved a new drug to treat a rare form of Amyotrophic Lateral Sclerosis (ALS), also commonly known as Lou Gehrig’s disease.
The U.S. Food and Drug Administration has approved a new drug to treat a rare form of Amyotrophic Lateral Sclerosis , also commonly known as Lou Gehrig’s disease.
The drug, Qalsody , is the first of its kind intended to treat an inherited type of ALS with mutations in the SOD1 gene that cause the breakdown of nerve cells essential for basic functions. "The approval was based on a reduction in plasma neurofilament light , a blood-based biomarker of axonal injury and neurodegeneration," the FDA said in a press release. "The findings are reasonably likely to predict a clinical benefit in patients. The observed reduction in NfL was consistent across all subgroups based on sex, disease duration since symptom onset, site of onset, and use of other medications for ALS treatment.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the diseaseThe FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.
Read more »
FDA grants accelerated approval to Biogen’s treatment for rare form of ALSThe U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.’s torferson, a treatment for a rare form of amyotrophic...
Read more »
FDA grants accelerated approval to Biogen treatment for rare form of ALSThe FDA has deemed Biogen's torferson reasonably likely to produce a clinical benefit for patients.
Read more »
Drug for rare form of ALS disease OK’d by FDABiogen’s injectable drug is for patients with a rare genetic mutation that’s estimated to affect less than 500 people in the U.S.
Read more »
FDA approves new drug for rare form of ALSThe FDA has approved a new drug to treat a rare form of amyotrophic lateral sclerosis, or ALS. The drug is expected to help people with a very specific mutation, SOD1, which applies to about 2% of the ALS population.
Read more »
FDA Gives Fast-Track Approval to New ALS DrugThe FDA fast-tracked the approval on the basis of early trial results.
Read more »